Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Jeffrey Neal Johnson

Down 45% Year-to-Date, Novo Nordisk Ignites a Price War

For investors in Novo Nordisk (NYSE: NVO), 2025 has been a challenging year. After reaching a 52-week high of over $112, the stock has declined by approximately 45%, reflecting mounting competitive pressures and concerns about slowing growth in its key GLP-1 franchise. But in a dramatic turn, the company has just made a decisive strategic move.

By slashing the direct-to-consumer (DTC) prices of its blockbuster drugs, Wegovy and Ozempic, to $349 per month, Novo Nordisk has upended its own business model. This raises a critical question for shareholders: Is this a desperate reaction to market pressure, or a calculated offensive to secure long-term dominance and reignite the stock's growth?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.